Cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody, are among the first targeted agents for CRC that have been approved by the Food and Drug Administration (FDA) [4,5,6]. This evidence concerns the gene EGFR and colorectal carcinoma.